Medical Editor: John P. Cunha, DO, FACOEP
Alphagan P (brimonidine tartrate) Ophthalmic Solution is an antiglaucoma medication used to treat open-angle glaucoma or ocular hypertension (high pressure inside the eye). Some strengths of Alphagan P are available in generic form. Common side effects of Alphagan P include:
- eye discomfort/itching/redness/burning/stinging,
- feeling like something is in your eye,
- blurred vision,
- redness of the eye or eyelid,
- swollen or puffy eyes,
- sensitivity to light,
- upset stomach,
- muscle pain,
- dry nose or mouth,
- sleep problems (insomnia), or
- unusual or unpleasant taste in your mouth.
Tell your doctor if you have unlikely but serious side effects of Alphagan P including:
- fast or pounding heartbeats,
- persistent headache,
- eye pain or swelling,
- extreme sensitivity to light, or
- vision changes.
The recommended dose of Alphagan P is one drop in the affected eye(s) three times daily, approximately 8 hours apart. It may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic product is to be used, the different products should be instilled at least 5 minutes apart. Alphagan P may interact with blood pressure medications, digoxin, beta-blockers, or antidepressants. Tell your doctor all medications you are taking. Alphagan P should be used only when prescribed during pregnancy. It is unknown if this medication passes into breast milk. Consult your doctor before breastfeeding.
Our Alphagan P (brimonidine tartrate) Ophthalmic Solution Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Stop using brimonidine and get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:
- slow or uneven heart rate;
- pounding heartbeats or fluttering in your chest;
- shallow breathing, feeling like you might pass out;
- severe swelling, redness, or discomfort in or around your eye;
- eye pain or increased watering; or
- numbness or tingly feeling in your hands or feet.
Less serious side effects may include:
- burning, stinging, or itching of your eyes;
- feeling like something is in your eye;
- blurred vision;
- redness of the eye or eyelid;
- mildly swollen or puffy eyes;
- sensitivity to light;
- nausea, upset stomach;
- headache, dizziness;
- muscle pain;
- tired feeling;
- sleep problems (insomnia);
- dry nose or mouth; or
- unusual or unpleasant taste in your mouth.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Alphagan-P (Brimonidine Tartrate)
Clinical Studies Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Adverse reactions occurring in approximately 10-20%of the subjects receiving brimonidine ophthalmic solution (0.1-0.2%) included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse reactions occurring in approximately 5-9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.
Adverse reactions occurring in approximately 1-4% of the subjects receiving brimonidine ophthalmic solution (0.1-0.2%) included: abnormal taste, allergic reaction, asthenia, blepharitis, blepharoconjunctivitis, blurred vision, bronchitis, cataract, conjunctival edema, conjunctival hemorrhage, conjunctivitis, cough, dizziness, dyspepsia, dyspnea, epiphora, eye discharge, eye dryness, eye irritation, eye pain, eyelid edema, eyelid erythema, fatigue, flu syndrome, follicular conjunctivitis, foreign body sensation, gastrointestinal disorder, headache, hypercholesterolemia, hypotension, infection (primarily colds and respiratory infections), insomnia, keratitis, lid disorder, pharyngitis, photophobia, rash, rhinitis, sinus infection, sinusitis, somnolence, stinging, superficial punctate keratopathy, tearing, visual field defect, vitreous detachment, vitreous disorder, vitreous floaters, and worsened visual acuity.
The following reactions were reported in less than 1% of subjects: corneal erosion, hordeolum, nasal dryness, and taste perversion.
The following reactions have been identified during postmarketing use of brimonidine tartrate ophthalmic solutions in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to brimonidine tartrate ophthalmic solutions, or a combination of these factors, include: bradycardia, depression, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions (including erythema, eyelid pruritus, rash, and vasodilation), syncope, and tachycardia. Apnea, bradycardia, coma, hypotension, hypothermia, hypotonia, lethargy, pallor, respiratory depression, and somnolence have been reported in infants receiving brimonidine tartrate ophthalmic solutions.
Read the entire FDA prescribing information for Alphagan-P (Brimonidine Tartrate)
© Alphagan-P Patient Information is supplied by Cerner Multum, Inc. and Alphagan-P Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.